miRagen Therapeutics Extends Series A
miRagen Therapeutics Inc., a Boulder, Colo.-based developer of microRNA therapeutics for cardiovascular and muscle diseases, has raised $4 million in new Series A funding, bringing the round total to $12 million. Amgen Ventures, Broadview Ventures and The Peierls Foundation joined existing shareholders Atlas Venture and Boulder Ventures.
2 June 2009•3 mins read
